Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

Inclusion Criteria

• Age 18 - 80 years old;
• Patients with active myeloma requiring systemic treatment;
• Newly diagnosed patients. Relapsed myeloma patients that have not previously had a transplant;
• Meeting criteria for high-risk disease;
• Measurable serum and/or urine M-protein from prior to induction therapy documented and available. A positive serum free lite assay is acceptable;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 (see Appendix C).
• Meet all institutional requirements for autologous stem cell transplantation;
• The patient must be able to comprehend and have signed the informed consent;
• Patients must have had > than PR after last therapy.

Exclusion Criteria

• Diagnosis of any of the following cancers:
• POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein [M-protein] and skin changes);
• Non-secretory myeloma (no measurable protein on Serum Free Lite Assay);
• Plasma cell leukemia;
• Diagnosis of amyloidosis;
• Failed to achieve at least a partial response (PR) to latest therapy;
• Previous hematopoietic stem cell transplantation;Patients can have had prior relapsed disease as long as they have never been previously transplanted;
• Known history of HIV infection;
• Use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection;
• Use of any myeloma-specific therapy within 21 days of bone marrow collection;
• Infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration;
• Participation in any clinical trial within 28 days of registration on this trial, which involved an investigational drug or device;
• History of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer;
• Active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is permitted.
• Human T-lymphotropic virus (HTLV) 1 or 2 positive;
• Known hypersensitivity to Prevnar or any of its components;
• Contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates).